ABBVIE INC.

Day range

$282.30 – $286.77

Open

$284.58

Prev close

$285.19

Volume

4.63M

Market cap

$503.96B

Shares out

1.77B

P/E

80.12

P/S

7.83

P/B

-84.91

P/FCF

27.68

ROE

-106.0%

ROA

4.7%

Debt/Equity

-11.93

Div yield

2.38%

As of Oct 22, 2026

• Board of directorsOct 15, 2026

  On October 14, 2026, AbbVie Inc. ("AbbVie") expanded the size of its Board of Directors (the "Board") from twelve directors to thirteen directors and appointed Dr. John M. Carethers as a Class II director. Dr. Carethers has been appointed to the Public Policy and Sustainability Committee of AbbVie.

• Guidance and outlookOct 5, 2026

  AbbVie's full-year 2026 adjusted diluted earnings per share guidance range, including the impact of third-quarter 2026 acquired IPR&D and milestones expense, is $13.76 - $13.96. AbbVie's third-quarter 2026 adjusted diluted earnings per share guidance range, including the impact of third-quarter 2026 acquired IPR&D and milestones expense, is $3.73 - $3.77.

• Deal completionsSep 3, 2026

  On September 3, 2026, AbbVie Inc. (the "Company") issued a press release announcing the completion of its acquisition of Apogee Therapeutics, Inc.

• Debt activityAug 18, 2026

  AbbVie completed its previously announced underwritten public offering of $500,000,000 aggregate principal amount of its senior floating rate notes due 2028, $1,000,000,000 aggregate principal amount of its 4.500% senior notes due 2028, $1,250,000,000 aggregate principal amount of its 4.650% senior notes due 2030, $1,500,000,000 aggregate principal amount of its 4.875% senior notes due 2031, $1,250,000,000 aggregate principal amount of its 5.050% senior notes due 2033, $1,500,000,000 aggregate principal amount of its 5.300% senior notes due 2036, $1,000,000,000 aggregate principal amount of its 5.450% senior notes due 2038, $1,500,000,000 aggregate principal amount of its 6.000% senior notes due 2056 and $500,000,000 aggregate principal amount of its 6.100% senior notes due 2066.

• Equity activityAug 5, 2026

  AbbVie Inc. entered into an underwriting agreement with Morgan Stanley & Co. LLC, BofA Securities, Inc., J.P. Morgan Securities LLC and SG Americas Securities, LLC, acting for themselves and as representatives of the several underwriters named in Schedule II therein, pursuant to which AbbVie agreed to issue and sell to the Underwriters [multiple series of notes].

• PFEPfizer Inc.-1.28%
• ABTAbbott Laboratories+1.16%
• JNJJohnson & Johnson-1.42%
• AMGNAmgen Inc-1.79%
• BMYBristol-Myers Squibb Co.-2.41%
• MRKMerck & Co., Inc.-1.34%
• LLYEli Lilly & Co.-2.54%
• GILDGilead Sciences Inc-0.73%

Days to cover

4.1

Short interest

16.28M

Avg volume

3.94M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential?
  positiveZacks Investment Research· Oct 23, 2026
• AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
  negativeZacks Investment Research· Oct 23, 2026
• Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy?
  neutralThe Motley Fool· Oct 23, 2026
• Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight
  positiveGlobeNewswire Inc.· Oct 22, 2026
• Vanguard Health Care ETF vs iShares U.S. Healthcare ETF
  positiveThe Motley Fool· Oct 21, 2026